Results 111 to 120 of about 757 (146)

Efficacy of Azvudine Therapy in Patients with Severe and Non-Severe COVID-19: A Propensity Score-Matched Analysis. [PDF]

Infect Drug Resist
Zhang S, Tan S, Yang B, Wu Y, Yuan G, Chen F, Liu L.   +6 more
europepmc   +1 more source

A Real-World Retrospective Study on the Efficacy and Safety of Four Antiviral Drugs for Hospitalized COVID-19 Patients: Nirmatrelvir/Ritonavir, Simnotrelvir/Ritonavir, Molnupiravir and Azvudine. [PDF]

Infect Drug Resist
Yu X, Luo R, Xie G, Ji J, Wang J, Li X, Qian X, Wang X.   +7 more
europepmc   +1 more source

Antiviral Effectiveness, Clinical Outcomes, and Artificial Intelligence Imaging Analysis for Hospitalized COVID-19 Patients Receiving Antivirals. [PDF]

Influenza Other Respir Viruses
Gao Y, Dong Y, Bu Q, Gong Z, Wang W, Zhou Z, Gao Y, Liu L, Wu M, Zhang J, Liang L, Li H, Jiang M, Luo Z, Ma Y, Zhang X, Hu Z.   +16 more
europepmc   +1 more source

Effects of graphene photothermal adjuvant therapy in patients infected with the Omicron BF.7 variant 2022: a prospective randomized controlled trial. [PDF]

Sci Rep
An C, Hao L, Li Y, Wu R, Li X, Zhou J, Chang Z, Ren X, Zheng H, Chen B, Wang H, Zheng W, Yan Y, Zhang K, Zhang J.   +14 more
europepmc   +1 more source

Identification of lead inhibitors for 3CLpro of SARS-CoV-2 target using machine learning based virtual screening, ADMET analysis, molecular docking and molecular dynamics simulations. [PDF]

RSC Adv
Chhetri SP, Bhandari VS, Maharjan R, Lamichhane TR.   +3 more
europepmc   +1 more source

Editorial: Drug development for respiratory infectious diseases and related complications in other systems. [PDF]

Front Med (Lausanne)
Yu X, Wang Y, Oliva A, Xue M.
europepmc   +1 more source

Azvudine and nirmatrelvir–ritonavir in hospitalized patients with moderate-to-severe COVID-19: Emulation of a randomized target trial [PDF]

Journal of Medical Virology, 2023
To examine the effectiveness of azvudine and nirmatrelvir-ritonavir in treating hospitalized patients with moderate-to-severe COVID-19. We emulated a target trial with a multicenter retrospective cohort of hospitalized adults with moderate-to-severe ...
Dan Liu, Sheyu Li, Yi Mao
exaly   +4 more sources

Some of the next articles are maybe not open access.

Related searches:

Azvudine and mortality in patients with coronavirus disease 2019: A retrospective cohort study

International Immunopharmacology, 2023
Several studies have found that azvudine (FNC) can inhibit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication both in vivo and in vitro. However, the effect of FNC on the risk of death in patients with coronavirus disease 2019 (COVID-19) is unclear.
Bin Liu, Mingjin Yang, Li Xu, Yishi Li, Jing Cai, Bo Xie, Kaican Zong, Shuliang Guo   +7 more
openaire   +2 more sources

Azvudine versus Paxlovid in COVID-19: A systematic review and meta-analysis

Reviews in Medical Virology
AbstractThis systematic review and meta‐analysis aimed to compare the effectiveness and safety of azvudine versus nirmatrelvir/ritonavir (Paxlovid) in treating coronavirus disease 2019 (COVID‐19). The researchers conducted searches on PubMed, Cochrane Library, Web of Science, medRxiv, and Google Scholar until January 2024.
Bahman Amani, Behnam Amani
exaly   +3 more sources

Separation and quantification of Azvudine in plasma of patients with COVID-19 using LC-MS/MS

Journal of Pharmaceutical and Biomedical Analysis, 2023
Azvudine (FNC) is a new drug conditionally approved in 2022 for the treatment of coronavirus disease 2019 (COVID-19) in China. However, the exposure level of FNC in COVID-19 patients in clinical practice is still obscure, and there is no liquid chromatography-tandem mass spectrometry (LC-MS/MS) or LC method reported for quantifying the FNC.
Zhijun Liu, Fengying Liang, Shouhong Gao, Xiujing Zhu, Xinhua Song, Wansheng Chen, Xia Tao, Zhipeng Wang, Deduo Xu   +8 more
openaire   +2 more sources